Purpose: The succinylation modification of lysine position plays an important role in the occurrence and development of tumors, but there are few reports in prostate cancer (PCa). This study aims to elucidate its expression in PCa and its clinical correlation with PCa.
Method: 95 tumor tissues, 3 normal tissues and 52 paired PCa paracancerous tissues were succinylated. 498 PCa samples with 20 succinylation modification-related genes were downloaded from TCGA for model construction. Statistical methods were used to analyze the data, including the non-negative matrix factorization (NMF) algorithm, the t distributed stochastic neighbor embedding (t-SNE) algorithm, and Cox regression analysis.
Results: pan-succinyllysine antibody staining showed that tumor tissue had higher succinyllysine levels than adjacent tissue (p0.001). Gleason grade and PDL1 expression levels were significantly different (p0.001) between high, medium and low succinylation staining scores. Using the RNA-seq data of 20 succinylation-related genes in the TCGA database, the prostate cancer tissue types were divided into four categories. Clinical characteristics of age, PSA level, and pathological stage showed differences among the four clusters. The expression of succinylation-related genes (KAT5, SDHD, and GLYATL1) and PCa-related genes (PDL1, AR, and TP53) was significantly different among the 52 matched tumors and adjacent tissues (p0.001). The expression of GLYATL1 and AR genes was significantly related to the pathological stage of PCa.
Conclusion: succinylation is significantly increased in PCa tissue and is closely related to Gleason grade and PD-L1 expression. Model construction of 20 succinylation modification-related genes showed that the later the pathological stage of prostate cancer, the higher the level of succinylation modification.

Distribution of anti-succinyllysine IHC staining of varying intensity in prostate cancer.
Zhang Z, Chen Y, Fang L, Zhao J, Deng S. The involvement of high succinylation modification in the development of prostate cancer. Front Oncol. 2022 Nov 1;12:1034605. doi: 10.3389/fonc.2022.1034605. PMID: 36387072; PMCID: PMC9663485.